These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14994845)

  • 1. Antiarrhythmic drug therapy of atrial fibrillation.
    VerNooy RA; Mounsey JP
    Cardiol Clin; 2004 Feb; 22(1):21-34. PubMed ID: 14994845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP; Cox CD
    Pharmacotherapy; 2001 Dec; 21(12):1514-29. PubMed ID: 11765303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
    Qin D; Leef G; Alam MB; Rattan R; Munir MB; Patel D; Khattak F; Adelstein E; Jain SK; Saba S
    J Cardiol; 2016 May; 67(5):471-6. PubMed ID: 26233885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation: rate control often better than rhythm control.
    Prescrire Int; 2004 Apr; 13(70):64-9. PubMed ID: 15148984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone.
    Shinagawa K; Shiroshita-Takeshita A; Schram G; Nattel S
    Circulation; 2003 Mar; 107(10):1440-6. PubMed ID: 12642367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiarrhythmic drug therapy in the treatment of atrial fibrillation.
    Jung F; DiMarco JP
    Cardiol Clin; 1996 Nov; 14(4):507-20. PubMed ID: 8950053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN; Mody FV; Lopez B; Sarma JS
    Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence.
    Slavik RS; Tisdale JE; Borzak S
    Prog Cardiovasc Dis; 2001; 44(2):121-52. PubMed ID: 11568824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
    Mykytsey A; Bauman JL; Razminia M; Zheutlin T; Wang T; Saleem M; Leal S; Kehoe RF
    J Cardiovasc Pharmacol Ther; 2007 Mar; 12(1):36-43. PubMed ID: 17495256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sequential antiarrhythmic treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic non-valvular atrial fibrillation.
    Kosior D; Opolski G; Torbicki A
    Med Sci Monit; 2001; 7(1):68-73. PubMed ID: 11208496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic effect of the Ca
    Kirchhoff JE; Diness JG; Abildgaard L; Sheykhzade M; Grunnet M; Jespersen T
    Pflugers Arch; 2016 Nov; 468(11-12):1853-1863. PubMed ID: 27722784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
    AFFIRM First Antiarrhythmic Drug Substudy Investigators
    J Am Coll Cardiol; 2003 Jul; 42(1):20-9. PubMed ID: 12849654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antiarrhythmic drugs for the treatment of atrial fibrillation.
    Castro A; Bianconi L; Santini M
    Pacing Clin Electrophysiol; 2002 Feb; 25(2):249-59. PubMed ID: 11916001
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
    Koenig A; Theolade R; Chauvin M; Brechenmacher C
    Presse Med; 1993 Nov; 22(36):1827-32. PubMed ID: 8309912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
    LaPointe NM; Pamer CA; Kramer JM
    Pharmacotherapy; 2003 Oct; 23(10):1316-21. PubMed ID: 14594348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF.
    Derakhchan K; Villemaire C; Talajic M; Nattel S
    Cardiovasc Res; 2001 Apr; 50(1):75-84. PubMed ID: 11282080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
    Humphries KH; Kerr CR; Steinbuch M; Dorian P;
    CMAJ; 2004 Sep; 171(7):741-5. PubMed ID: 15451836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
    Wirth KJ; Knobloch K
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):166-74. PubMed ID: 11218069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.